the future of biomedical research is in jeopardy as the National Institutes of Health (NIH) faces potential funding cuts and delays. An analysis from STAT News in April indicated that NIH funding has already decreased by at least $2.3 billion as the start of the year. KFF Health News reported that approximately 780 NIH grants were either fully or partially terminated between February 28 and March 28 alone. Further reductions are anticipated, including proposed cuts to indirect costs.

Despite this uncertainty, experts emphasize the notable value of NIH grant funding as a driver of both economic activity and improvements in public health.

A recent report by United for Medical Research revealed that in fiscal year 2024,NIH-funded research generated $94.58 billion in economic activity across the nation, representing a 156% return on investment.The report also noted that NIH funding supported 407,782 jobs nationwide. According to the NIH’s own figures, patents resulting from its funded work produce 20% more economic value compared to other U.S. patents.

Beyond the economic benefits, NIH funding plays a crucial role in enhancing the quality of life and increasing longevity for individuals, families, and communities.

Quantifying the precise impact of NIH-funded research on human health is challenging, but proxy measures exist. As an example, a study published in JAMA Health Forum found that NIH funding supported the growth of 386 out of 387 drugs approved by the Food and Drug administration (FDA) between 2010 and 2019. Many of these drugs address critical health issues such as cancer, diabetes, cardiovascular disease, infectious diseases, and neurological disorders like Parkinson’s disease.

ancient Impact of NIH Funding

Many advancements now considered common knowledge, such as the link between cholesterol and cardiovascular health, or standard practices like newborn screenings for treatable diseases, were initially made possible through NIH funding. These discoveries highlight the transformative potential of NIH funding and the risks associated with its reduction.

The biotechnology industry itself emerged from NIH-supported research. In the 1970s, Stanley Cohen and Herbert Boyer pioneered DNA cloning and gene transplantation between organisms, laying the foundation for this industry.

Two decades later, the NIH and the Department of Energy launched a 13-year project to sequence the human genome, largely through university research grants. By 2003, researchers had sequenced 92% of the human genome. In 2022, a team primarily funded by the NIH’s National Human Genome Research Institute achieved a complete human genome sequence. This breakthrough has facilitated advancements in understanding inherited diseases, pharmacogenomics, and precision medicine.

“NIH funding produces astonishing results. Cuts will set scientific research back and result in losses in quality of life and longevity.”

NIH funding has also been instrumental in cancer treatment breakthroughs. In 1948, Sidney Farber demonstrated the first accomplished use of chemotherapy, using aminopterin to induce remission in children with acute leukemia. Before Farber’s NIH-supported research, children with this condition had little chance of surviving beyond five years.

Advancements in Cancer Treatment

Immunotherapy and other cancer treatments have since emerged, progressing from initial research to drug development and clinical trials with NIH support. This includes the development of CAR T cell therapy, which genetically modifies a patient’s own T-cells to combat cancer. CAR T cell therapy has improved outcomes for patients with persistent blood cancers, and ongoing trials are exploring its potential for treating other cancers.

In the 1990s, scientists, with NIH funding, identified the BRCA1 and BRCA2 genes responsible for inherited predispositions to breast and other cancers. Today, BRCA gene testing informs decisions about prevention, screening, and treatment.

These advancements, along with improvements in detection and screening, have substantially reduced cancer mortality rates. According to the American cancer Society, U.S. mortality rates from all cancers dropped by 34% between a smoking-related peak in 1991 and 2022. For children with acute leukemias, the five-year survival rate has dramatically increased from almost zero to approximately 90% for acute lymphocytic leukemia and 65-70% for acute myelogenous leukemia.

These examples represent only a portion of the progress made through decades of research.Current NIH funding cuts threaten future breakthroughs necesary for better care, technology,